Goodwin Biotechnology recently licensed an electronic content and document management solution to enhance the efficiency and effectiveness of its quality systems and operations. This improvement continues to ensure that Goodwin remains uniquely positioned as a qualified and flexible biopharmaceutical contract development and manufacturing organization (CDMO) that offers an integrated Single Source Solution from cell line development, process development and cGMP manufacturing including scale-up, cGMP contract manufacturing, and aseptic fill/finish of mammalian cell-culture derived monoclonal antibodies, recombinant proteins, vaccines, and antibody drug conjugates (ADCs).
 
“Acquisition and implementation of this sophisticated electronic solution demonstrates Goodwin’s commitment to providing top-tier development and manufacturing services for our clients,” said Karl Pinto, chief executive officer, Goodwin Biotechnology. “Goodwin’s past successes supporting our clients through their early- and late-stage clinical trials, and regulatory compliant commercial manufacturing, will be strengthened through this recent investment. These strategic steps demonstrate our commitment to effectively support our clients through all stages of product development and cGMP manufacturing to assure conformance to worldwide regulatory standards.”